FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

FOCUS ON RESEARCH Previous Volume 356:771-773 February 22, 2007 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Perspective Perspective by Zheng, Z. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Zheng, Z. PubMed Citation

Lung cancer, the most common cause of cancer deaths globally, results in about 1 million deaths each year. Despite advances in treatment over the past two decades, the improvement in long-term survival has been limited: only about 15% of patients survive for 5 years or longer. The high mortality is due mainly to early and widespread dissemination of the cancer, which means that surgical removal of early-stage non–small-cell lung cancer results in the best chance for long-term survival. Chemotherapy for advanced non–small-cell lung cancer (which accounts for about 85% of all lung cancers) or as adjuvant treatment for patients with . . . [Full Text of this Article]

Source Information

Dr. Gazdar is deputy chief of the Hamon Center for Therapeutic Oncology and a professor of pathology at the University of Texas Southwestern Medical Center, Dallas.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.